¼¼°èÀÇ µ¶¼Ò·çºñ½Å ½ÃÀå
Doxorubicin
»óǰÄÚµå : 1526240
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 288 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,260,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,780,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

µ¶¼Ò·çºñ½Å ¼¼°è ½ÃÀåÀº 2030³â±îÁö 17¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2023³â¿¡ 11¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â µ¶¼Ò·çºñ½Å ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2023-2030³â¿¡ CAGR 5.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 17¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ À¯¹æ¾Ï ¿ëµµ´Â CAGR 5.6%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 3¾ï 7,410¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Æó¾Ï ¿ëµµ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 7.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 6,880¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ µ¶¼Ò·çºñ½Å ½ÃÀåÀº 2023³â¿¡ 4¾ï 6,880¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2023-2030³â°£ CAGR 8.1%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿©, 2030³â¿¡´Â 1¾ï 4,500¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 4.4%¿Í 5.8%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.7%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°è µ¶¼Ò·çºñ½Å ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

µ¶¼Ò·çºñ½ÅÀº À¯¹æ¾Ï, ¹æ±¤¾Ï, Ä«Æ÷½ÃÀ°Á¾, ¸²ÇÁÁ¾, ±Þ¼º ¸²ÇÁ¸ð±¸¹éÇ÷º´ µî ´Ù¾çÇÑ ¾Ï Ä¡·á¿¡ ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â °­·ÂÇÑ È­Çпä¹ýÁ¦ÀÔ´Ï´Ù. ÅäÆ÷À̼ҸӶóÁ¦ II¶ó´Â È¿¼Ò¸¦ ¾ïÁ¦ÇÏ¿© ÀÛ¿ëÇÕ´Ï´Ù. ÀÌ ÀÛ¿ëÀ» ÅëÇØ ¾Ï¼¼Æ÷ÀÇ º¹Á¦¸¦ ¸·°í ¾Ï¼¼Æ÷¸¦ »ç¸ê½Ãŵ´Ï´Ù. µ¶¼Ò·çºñ½ÅÀº ÀϹÝÀûÀ¸·Î Á¤¸ÆÀ¸·Î Åõ¿©µÇ¸ç ƯÀ¯ÀÇ ºÓÀº »öÀ¸·Î À¯¸íÇϸç, °­·ÂÇÑ È¿°ú¿Í ½É°¢ÇÑ ºÎÀÛ¿ëÀ¸·Î ÀÎÇØ 'ºÓÀº ¾Ç¸¶'¶ó´Â º°¸íÀÌ ºÙ¾ú½À´Ï´Ù. ±× È¿°ú¿¡µµ ºÒ±¸ÇÏ°í µ¶¼Ò·çºñ½ÅÀÇ »ç¿ëÀº ½Éµ¶¼º¿¡ ÀÇÇØ Á¦ÇѵǸç, ÁÖÀÇ ±í°Ô ¸ð´ÏÅ͸µÇÏ°í °ü¸®ÇÏÁö ¾ÊÀ¸¸é µ¹ÀÌų ¼ö ¾ø´Â ½ÉÀå ¼Õ»óÀ» ÀÏÀ¸Å³ ¼ö ÀÖ½À´Ï´Ù.

µ¶¼Ò·çºñ½ÅÀÇ Á¦Çü°ú Àü´Þ ¹æ¹ýÀº Ä¡·á Áö¼ö¸¦ ³ôÀÌ°í µ¶¼º ºÎÀÛ¿ëÀ» ÁÙÀÌ´Â °ÍÀ» ¸ñÇ¥·Î Å« ÁøÀüÀ» ÀÌ·ç¾ú½À´Ï´Ù. ÀÌ ºÐ¾ßÀÇ Å« µ¹ÆÄ±¸ Áß Çϳª´Â ¸®Æ÷Á» µ¶¼Ò·çºñ½ÅÀÇ °³¹ß·Î, ¸®Æ÷Á»¿¡ ¾à¹°À» ĸ½¶È­ÇÏ¿© Á¤»ó Á¶Á÷À» º¸Á¸Çϸ鼭 Á¾¾ç ¼¼Æ÷¿¡ º¸´Ù Ç¥ÀûÈ­µÈ Àü´ÞÀ» °¡´ÉÇÏ°Ô Çß½À´Ï´Ù. ÀÌ·¯ÇÑ °³¼±Àº ½Éµ¶¼º ¹× ±âŸ Àü½Å ºÎÀÛ¿ëÀ» °¨¼Ò½ÃÄÑ È¯ÀÚ°¡ ´õ Àß °ßµô ¼ö ÀÖ´Â Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¶ÇÇÑ, ÇöÀç ÁøÇà ÁßÀÎ ¿¬±¸µéÀº µ¶¼Ò·çºñ½ÅÀÇ Æ¯À̼º°ú È¿´ÉÀ» ´õ¿í Çâ»ó½Ã۱â À§ÇØ ³ª³ëÀÔÀÚ ¹× ±âŸ »õ·Î¿î ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ »ç¿ëÀ» °í·ÁÇϰí ÀÖ½À´Ï´Ù. Á¤¹Ð ÀÇÇÐÀÇ ¹ßÀüÀº ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸ鼭 Ä¡·á È¿°ú¸¦ ±Ø´ëÈ­Çϱâ À§ÇØ È¯ÀÚ °³°³ÀÎÀÇ ÇÁ·ÎÆÄÀÏÀ» ±â¹ÝÀ¸·Î ÇÑ °³º°È­µÈ Åõ¿© ¿ä¹ýÀ» À§ÇÑ ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù.

µ¶¼Ò·çºñ½Å ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è ¾Ï ¹ßº´·ü Áõ°¡´Â ´õ ¸¹Àº ȯÀÚµéÀÌ È¿°úÀûÀÎ È­Çпä¹ý ¿É¼ÇÀ» ÇÊ¿ä·Î ÇÏ´Â Áß¿äÇÑ ÃËÁøÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ¸®Æ÷Á» Á¦Á¦ ¹× ³ª³ë ÀÔÀÚ¿Í °°Àº ¾à¹° Àü´Þ ±â¼úÀÇ ¹ßÀüÀº µ¶¼Ò·çºñ½ÅÀÇ È¿´É°ú ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» °³¼±ÇÏ¿© µ¶¼Ò·çºñ½ÅÀÇ º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤¹ÐÀÇÇÐ(Precision Medicine) ºÐ¾ßÀÇ È®´ë´Â º¸´Ù ¸ÂÃãÈ­µÈ Ä¡·á ¿ä¹ýÀÇ °³¹ßÀ» Áö¿øÇϰí, º´¿ë¿ä¹ý¿¡¼­ µ¶¼Ò·çºñ½ÅÀÇ »ç¿ëÀ» Áõ°¡½Ãų ¼ö ÀÖ½À´Ï´Ù. Á¦¾à»çµéµµ µ¶¼Ò·çºñ½ÅÀ» Æ÷ÇÔÇÑ »õ·Î¿î ÀûÀÀÁõ°ú º´¿ë¿ä¹ýÀ» ¸ð»öÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÅÈï ½ÃÀåÀÇ ÀÇ·á ÀÎÇÁ¶ó °³¼±°ú ¾Ï Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»óÀ¸·Î È¿°úÀûÀÎ È­Çпä¹ýÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ±â¼ú ¹ßÀü, ¾Ï ¹ßº´·ü Áõ°¡, Áö¼ÓÀûÀÎ ¿¬±¸ ³ë·ÂÀ¸·Î ÀÎÇØ µ¶¼Ò·çºñ½Å ½ÃÀåÀÌ ¿ªµ¿ÀûÀ¸·Î ÁøÈ­Çϰí ÀÖÀ½À» µÞ¹ÞħÇÕ´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 59°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Doxorubicin Market to Reach US$1.7 Billion by 2030

The global market for Doxorubicin estimated at US$1.1 Billion in the year 2023, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2023-2030. Breast Cancer Application, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$374.1 Million by the end of the analysis period. Growth in the Lung Cancer Application segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$468.8 Million While China is Forecast to Grow at 8.1% CAGR

The Doxorubicin market in the U.S. is estimated at US$468.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$145.0 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Doxorubicin Market - Key Trends & Drivers Summarized

Doxorubicin is a potent chemotherapy drug commonly used to treat various types of cancer, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphoblastic leukemia. Discovered in the 1960s, doxorubicin belongs to the anthracycline class of drugs, which work by intercalating DNA strands and inhibiting the enzyme topoisomerase II. This action prevents the replication of cancer cells, leading to their death. Doxorubicin is typically administered intravenously and is known for its distinctive red color, earning it the nickname "Red Devil" due to its potent effects and significant side effect profile. Despite its efficacy, the use of doxorubicin is limited by its cardiotoxicity, which can lead to irreversible heart damage if not carefully monitored and managed.

The formulation and delivery methods of doxorubicin have seen significant advancements aimed at enhancing its therapeutic index and reducing its toxic side effects. One of the major breakthroughs in this area is the development of liposomal doxorubicin, which encapsulates the drug in liposomes, allowing for more targeted delivery to tumor cells while sparing healthy tissues. This modification has been shown to reduce cardiotoxicity and other systemic side effects, making treatment more tolerable for patients. Additionally, ongoing research is exploring the use of nanoparticles and other novel drug delivery systems to further improve the specificity and efficacy of doxorubicin. Advances in precision medicine are also paving the way for personalized dosing regimens based on individual patient profiles, aiming to maximize therapeutic outcomes while minimizing adverse effects.

The growth in the doxorubicin market is driven by several factors. The increasing incidence of cancer globally is a significant driver, as more patients require effective chemotherapeutic options. Advances in drug delivery technologies, such as liposomal formulations and nanoparticles, are enhancing the efficacy and safety profile of doxorubicin, encouraging its wider adoption. Furthermore, the expanding field of precision medicine is supporting the development of more tailored treatment regimens, potentially increasing the use of doxorubicin in combination therapies. Pharmaceutical companies are also investing heavily in research and development to explore new indications and combination treatments involving doxorubicin. Additionally, improvements in healthcare infrastructure and increased access to cancer treatment in emerging markets are boosting the demand for effective chemotherapy agents. These factors collectively underscore the dynamic and evolving nature of the doxorubicin market, driven by technological advancements, rising cancer prevalence, and ongoing research efforts.

Select Competitors (Total 59 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â